Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01393223 | Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome | PHASE2 | COMPLETED | 21 | — | — | Jul 21, 2015 | Jun 14, 2018 | Nov 1, 2018 | 1 | United States |
The number/severity of adverse events throughout the study
| Arm | Type | Description |
|---|---|---|
| LP-08 80mg | ACTIVE_COMPARATOR | 4 weekly intravesical administration of LP-08 80mg |
| LP-08 20mg | ACTIVE_COMPARATOR | 4 weekly intravesical administration of LP-08 20mg |
| Normal Saline | PLACEBO_COMPARATOR | Four weekly normal saline intravesical administration |
| Name | Type | Description |
|---|---|---|
| LP-08 80mg | DRUG | Intravesical instillation of 80mg LP08 |
| Normal saline | DRUG | Intravesical instillation of normal saline |
| LP-08 20mg | DRUG | Intravesical instillation of 20mg LP08 |
Inclusion Criteria: A patient is deemed suitable for inclusion in the study if the patient meets the following criteria: 1. Male or female at least 18 years of age 2. IC/BPS diagnosed by a health care provider based the following criteria: Complaint of suprapubic pain related to bladder fillin...